// App-Quantinova.ai

FR-OR19 : Dapagliflozin Reduces the Risk of Hyperkalaemia in Patients with Heart Failure and Reduced Ejection Fraction: A Secondary Analysis from DAPA-HF

Researchers

Presenter

  • Kristensen S�ren�Lund

Principal Investigators

  • Docherty KieranF

  • Jhund Pardeep

  • Bengtsson Olof

  • Inzucchi SilvioE

  • Kosiborod Mikhail

  • Langkilde Anna Maria

  • Martinez Felipe

  • Ponikowski Piotr

  • Sabatine MarcS

  • Sjostrand Mikaela

  • Solomon ScottD

  • McMurray John

Medical Centers

  • NSGO & Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark

  • Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom

  • AstraZeneca, Gothenburg, Sweden

  • Yale University, New Haven, Connecticut, United States

  • St Lukes Mid America Heart Institute Kansas City Kansas United States

  • National Univ of Cordoba, Cordoba, Argentina

  • Wroclaw Medical University, Wroclaw, Poland

  • Brigham and Womens Hospital, Brookline, Massachusetts, United States

Locations

  • Denmark

  • United Kingdom

  • Sweden

  • United States

  • Argentina

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Heart failure with reduced ejection fraction

  • Hyperkalaemia

Biomarkers

  • N/A

Drug/Treatment

  • Dapagliflozin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved